Erin J. Howell

Erin J. Howell

New York

Email erin.howell@​

Phone +1 212 918 3634

Fax +1 212 918 3100

Practice groupCorporate & Finance

Erin Howell knows that a valuable adviser needs both breadth and depth of knowledge. That's her key to advising clients across a broad range of industries on their most important corporate transactions, while maintaining a particular focus on key industries. From life sciences to life insurance, Erin has counseled clients on a variety of business, corporate, and regulatory matters.

Erin focuses on U.S. and international mergers and acquisitions, internal reorganizations, and asset purchase and sale transactions – including pharmaceutical products and blocks of insurance business. Erin has represented clients in industries as varied as financial services, pharmaceuticals and life sciences, textiles, transportation, and health services. Within the insurance industry, she brings a decade of experience dealing with complex reinsurance, transactional, and regulatory matters, including M&A, renewal rights, shell acquisitions, and regulatory issues for insurance underwriters, producers, and reinsurers.

Awards and recognitions


Legal Aid Society Recognition Award

Education and admissions


J.D., University of California, Berkeley School of Law, 2008

B.A., Michigan State University, summa cum laude, 2003


Member, LGBT Bar Association of Greater New York

Bar admissions and qualifications

New York

Representative experience

Novartis on its acquisition of Amblyotech, a U.S.-based software startup, pursuing the development of digital therapy for the treatment of amblyopia.

Medicines Development for Global Health on the sale of its Priority Review Voucher.

Novartis on its licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates.

Novartis in connection with a strategic collaboration with Cellular Biomedicine Group, Inc. to manufacture and supply the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China.

Celgene on the entry into a strategic collaboration and licensing agreement with Kyn Therapeutics with an $80 million upfront payment.

Helsinn Healthcare SA in connection with the acquisition of the worldwide rights to Valchlor©/Ledaga© from Actelion Pharmaceuticals, Ltd.

Kiadis, a clinical stage biopharmaceutical company, on its acquisition of US-based CytoSen Therapeutics, Inc.

Elastagen Pty Ltd in relation to its sale to Allergan plc for up to US$260m.

Gemalto, on its acquisition of Smartrac's U.S. business.

A leading global life sciences company on its minority investment in a clinical lab, with an option to acquire.

Airbus, on its acquisition of MTM Robotics, a Seattle-based technology company that creates automated assembly and control systems.

A Bermuda-based reinsurance company in acquiring U.S. insurance companies.

A global transportation company in a strategic investment in a small business.

Regular representation of international property/casualty insurer in preparation of Holding Company Act filings.

A publicly held insurer in divesting non-core insurance business.

Loading data